- Pfizer slashes revenue forecast on lower COVID sales, will cut costs Reuters
- Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump CNBC
- Pfizer slashes outlook: Projects weak demand for Covid-19 vaccine and Paxlovid CNBC Television
- Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance Pfizer
- Pfizer stock sinks as pharma giant cuts earnings outlook on weaker COVID demand MarketWatch
- View Full Coverage on Google News
Source link